Glutamate receptor modulators and therapeutic agents
View Patent ↗The present invention discloses methods of modulating the activity of Group I mGluRs using a defined class of benzamide compounds. In one embodiment, methods of modulating the activity of mGluR1 are provided. In another embodiment, methods of modulating the activity of mGluR5 are provided. In still another embodiment, methods of simultaneously modulating the activities of both mGluR1 and mGluR5 are provided. The present invention also provides methods of treating diseases or disorders which are mediated in full or in part by Group I mGluRs using one or more compounds belonging to the defined class of benzamide compounds. The present invention further provides methods of preventing diseases or disorders which are mediated in full or in part by Group I mGluRs using one or more compounds belonging to the defined class of compounds. Diseases and disorders contemplated include, inter alia, diseases and disorders of the central nervous system, the peripheral nervous system, the gastrointestinal system, the circulatory system, skin, retina, brain, heart, and lungs.
1. A compound with the formula
wherein
R 4 is selected from the group consisting of H, Cl, Br, F, CH 3 , OCH 3 , CF 3 , OCF 3 , and phenyl; R 6 is selected from the group consisting of sarcosine-N-carbonyl,
CO—N-Me-Gly-Gly-Gly, CO—N-Me-Gly-Glu-Glu, CO—N-Me-Gly-Lys-Lys, CO-Pro-Glu-Glu, CO-Pro-Lys-Lys, CO-Pro-Gly-Lys, and CO-Pro-Lys-Lys,
CON-Me-Xaa, and CON-Me-Xaa-Xaa wherein Xaa is Ala, Leu, Gly, Ile, Val, Ser, Trp,Thr, Lys, His, Cys, Met, Arg, Phe, Tyr, Glu, Gln, Orn, Asp, or Asn; and R 7 , R 8 , R 9 and R 10 are each independently chosen from the group consisting of H, Cl, Br, F, CH 3 , CH 2 CH 3 , CH 2 Ph, CH═CH 2 , C≡CH, C≡N, OCH 3 , OCF 3 , Ph, OPh, and NO 2 .
2. A pharmaceutical composition including as active agent an effective amount of a compound of the formula:
wherein
R 4 is selected from the group consisting of H, Cl, Br, F, CH 3 , OCH 3 , CF 3 , OCF 3 , and phenyl; R 6 is selected from the group consisting of sarcosine-N-carbonyl,
CO—N-Me-Gly-Gly-Gly, CO—N-Me-Gly-Glu-Glu, CO—N-Me-Glu-Glu-OH, CO—N-Me-Gly-Lys-Lys, CO-Pro-Glu-Glu, CO-Pro-Lys-Lys, CO-Pro-Gly-Lys, CON-Me-Xaa, and CON-Me-Xaa-Xaa
wherein Xaa is Ala, Leu, Gly, Ile, Val, Ser, Trp, Thr, Lys, His, Cys, Met, Arg, Phe, Tyr, Glu, Gln, Orn, Asp, or Asn; and R 7 , R 8 , R 9 , and R 10 are each independently chosen from the group consisting of H, Cl, Br, F, CH 3 , CH 2 CH 3 , CH 2 Ph, CH═CH 2 , C≡CH, C≡N, OCH 3 , OCF 3 , Ph, OPh, and NO 2 .
3. A compound according to claim 1 having the structure
wherein
R4 is selected from the set consisting of H, Cl, Br, F, CH 3 , OCH 3 , CF 3 , OCF 3 , and phenyl;
R7, R8, R9, and R10 are each independently chosen from the group consisting of Cl, Br, F, CH 3 , CH 2 CH 3 , CH 2 Ph, CH═CH 2 , C≡CH, C≡N, OCH 3 , OCF 3 , Ph, OPh, and NO 2 .
4. A compound according to claim 1 selected from the group consisting of
5. The compound according to claim 1 having the structure
6. The pharmaceutical composition of claim 2 including as active agent an effective amount of a compound of the formula:
wherein
R4 is selected from the set consisting of H, Cl, Br, F, CH 3 , OCH 3 , CF 3 , OCF 3 , and phenyl;
R7, R8, R9, and R10 are each independently chosen from the group consisting of Cl, Br, F, CH 3 , CH 2 CH 3 , CH 2 Ph, CH═CH 2 , C≡CH, C≡N, OCH 3 , OCF 3 , Ph, OPh, and NO 2 .
7. The composition of claim 2 including as active agent an effective amount of a compound selected from the group consisting of
8. The composition of claim 2 including as active agent an effective amount of the compound